Segment Reporting - Schedule of Segment Operating Expenses Including Segment Expenses, and Net Loss (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||||
| Operating expenses: | ||||||||||
| Direct research and development | $ 60,080 | $ 58,195 | $ 146,091 | $ 99,473 | ||||||
| Total operating expenses | 112,490 | 80,141 | 237,622 | 137,335 | ||||||
| Loss from operations | (112,490) | (80,141) | (237,622) | (137,335) | ||||||
| Other income (expense): | ||||||||||
| Interest income | 5,348 | 6,320 | 11,703 | 13,226 | ||||||
| Interest expense | (1,848) | (1,874) | (3,671) | (3,667) | ||||||
| Segment and consolidated net loss | 109,473 | $ 121,032 | 76,531 | $ 51,694 | 230,505 | 128,225 | ||||
| Operating Segments [Member] | ||||||||||
| Operating expenses: | ||||||||||
| Payroll and related | 48,543 | 25,193 | 90,584 | 45,950 | ||||||
| Commercial planning | 15,057 | 3,822 | 23,040 | 6,986 | ||||||
| Depreciation and amortization | 132 | 119 | 272 | 204 | ||||||
| Other segment items* | [1] | 17,383 | 14,873 | 33,200 | 26,525 | |||||
| Total operating expenses | 112,490 | 80,141 | 237,622 | 137,335 | ||||||
| Loss from operations | (112,490) | (80,141) | (237,622) | (137,335) | ||||||
| Other income (expense): | ||||||||||
| Interest income | 5,348 | 6,320 | 11,702 | 13,226 | ||||||
| Interest expense | (1,848) | (1,874) | (3,671) | (3,667) | ||||||
| Other segment items** | [2] | (483) | (836) | (914) | (449) | |||||
| Segment and consolidated net loss | (109,473) | (76,531) | (230,505) | (128,225) | ||||||
| Operating Segments [Member] | Clinical Trials [Member] | ||||||||||
| Operating expenses: | ||||||||||
| Direct research and development | 15,633 | 12,636 | 44,329 | 24,630 | ||||||
| Operating Segments [Member] | Contract Manufacturing [Member] | ||||||||||
| Operating expenses: | ||||||||||
| Direct research and development | $ 15,742 | $ 23,498 | $ 46,197 | $ 33,040 | ||||||
| ||||||||||
| X | ||||||||||
- Definition The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Commercial Planning Expenses No definition available.
|
| X | ||||||||||
- Definition Payroll and related expenses. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|